ALK and non-small cell lung carcinoma: After the approval of crizotinib targeting ALK+ IMT, ceritinib and other generations of ALK-TKIs have proven their efficacy in some cases, and follow a similar pattern as in ALK+ NSCLC, which should be further confirmed with cohort studies.